Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 1;98(1):56-64.
doi: 10.1016/j.biopsych.2025.01.001. Epub 2025 Jan 9.

Focused Ultrasound Neuromodulation: Exploring a Novel Treatment for Severe Opioid Use Disorder

Ali Rezai  1 , Daisy G Y Thompson-Lake  2 , Pierre-François D'Haese  3 , Nathalie Meyer  4 , Manish Ranjan  1 , Daniel Farmer  5 , Victor Finomore  2 , Jennifer L Marton  2 , Sally Hodder  6 , Jeffrey Carpenter  3 , Aniruddha Bhagwat  1 , James Berry  5 , Padma Tirumalai  2 , Geoffrey Adams  2 , Tasneem A Arsiwala  2 , Olaf Blanke  4 , James J Mahoney 3rd  7
Affiliations

Focused Ultrasound Neuromodulation: Exploring a Novel Treatment for Severe Opioid Use Disorder

Ali Rezai et al. Biol Psychiatry. .

Abstract

Background: Opioid use disorder remains a critical health care challenge because current therapeutic strategies have limitations that result in high recurrence and deaths. We evaluated the safety and feasibility of focused ultrasound (FUS) neuromodulation to reduce substance cravings and use in severe opioid and co-occurring substance use disorders.

Methods: This prospective, open-label, single-arm study enrolled 8 participants with severe, primary opioid use disorder with co-occurring substance use. Participants received a 20-minute session of low-intensity FUS (220 kHz) neuromodulation targeting the bilateral nucleus accumbens (NAc) with follow-up for 90 days. Outcome measures included safety, tolerability, feasibility, and effects of FUS neuromodulation by assessment of adverse events, substance craving, substance use (self-report, urine toxicology), mood, neurological examinations, and anatomical and functional magnetic resonance imaging (fMRI) at 1, 7, 30, 60, and 90 days post-FUS.

Results: No serious device-related adverse events or imaging abnormalities were observed. Following FUS, participants demonstrated immediate (p < .002) and sustained (p < .0001; mean 91%) reductions in cue-induced opioid craving, with median ratings on a scale from 0 to 10 as follows: 6.9 (pre-FUS) versus 0.6 (90-day post-FUS). Craving reductions were similar for other illicit substances (e.g., methamphetamine [p < .002], cocaine [p < .02]). Decreases in opioid and co-occurring substance use were confirmed by urine toxicology. Seven participants remained abstinent at 30 days; 5 participants remained abstinent throughout 90 days post-FUS. Resting-state fMRI demonstrated decreased connectivity from the NAc to reward and cognitive regions post-FUS.

Conclusions: NAc FUS neuromodulation is safe and a potential adjunctive treatment for reducing drug cravings and use in individuals with severe opioid and co-occurring substance use disorders. Larger, sham-controlled, randomized studies are warranted.

Keywords: Addiction; Focused ultrasound; Neuromodulation; Overdose; Substance use disorder.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURES

All authors report no biomedical financial interests or potential conflicts of interest.

References

    1. Ahmad FB, Cisewski JA, Rossen LM, Sutton P (2024): Provisional drug overdose death counts. National Center for Health Statistics. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm Accessed April 7, 2024
    1. Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, et al. (2011): Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry 68(12): 1238–1246. doi: 10.1001/archgenpsychiatry.2011.121 - DOI - PMC - PubMed
    1. Nunes EV, Gordon M, Friedmann PD, Fishman MJ, Lee JD, Chen DT, et al. (2018): Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone. J Subst Abuse Treat 85: 49–55. doi: 10.1016/j.jsat.2017.04.016 - DOI - PMC - PubMed
    1. Hodder SL, Feinberg J, Strathdee SA, Shoptaw S, Altice F, Ortenzio L, Beyrer C (2021): HIV and overdoses: diversifying therapies for opioid use disorder - Authors’ reply. Lance 398(10302): 742. doi: 10.1016/S0140-6736(21)01221-6 - DOI - PubMed
    1. Hassan AN, Le Foll B (2019): Polydrug use disorders in individuals with opioid use disorder. Drug Alcohol Depend 198: 28–33. doi: 10.1016/j.drugalcdep.2019.01.031 - DOI - PubMed

LinkOut - more resources